介入心脏病学

Persistent Risk of Cardiac Structural Complications in TAVR: A Decade-Long Analysis Reveals High Mortality and Stagnant Incidence

By MedXY 03/02/2026

A 10-year multicenter study highlights that cardiac structural complications (CSCs) affect 2.1% of TAVR recipients. With a 35% 30-day mortality rate and no decline in incidence over a decade, these events remain a formidable challenge for interventional cardiology teams despite advancing technology.

Cardiology news

Isolated Coronary Artery Ectasia: A High-Risk Phenotype Associated with Doubled Recurrent Infarction Rates

By MedXY 03/02/2026

A retrospective study reveals that patients with myocardial infarction caused by isolated coronary artery ectasia face significantly higher risks of recurrence and stent thrombosis compared to those without ectasia, highlighting a critical need for tailored antithrombotic strategies in this unique patient population.

Cardiology news

Bridging the Gap: Understanding In-Procedure Variability and Quality Control in the FAVOR III Europe QFR Analysis

By MedXY 02/03/2026

The REPEAT-QFR study reveals a modest 72% diagnostic agreement between bedside and core-lab QFR. The findings underscore that angiographic quality and strict adherence to standard operating procedures are essential for accurate, non-invasive coronary physiology assessment in clinical practice.

Cardiology news

The Achilles’ Heel of Left Main Bifurcation: Circumflex Ostium Remains the Primary Site of Restenosis Regardless of Stenting Strategy

By MedXY 01/18/2026

A subanalysis of the EBC MAIN trial reveals that the circumflex ostium is the most frequent site of restenosis following left main bifurcation stenting, occurring in 71% of patients requiring revascularization, regardless of whether a single- or dual-stent technique was employed.

Cardiology Neurology news

Vanishing Act: Novel Biodegradable PFO Closure Device Matches Nitinol Efficacy in Landmark Randomized Trial

By MedXY 01/17/2026

A multicenter randomized trial confirms that a novel biodegradable PFO closure device is noninferior to nitinol devices, achieving high closure rates and disappearing from echocardiography within two years, potentially reducing long-term foreign body risks in cryptogenic stroke patients.